Gain detailed insights into the trading activity of Congress members for Akero Therapeutics on our government trades page. Stay updated on how elected officials are investing in AKRO.

Akero Therapeutics - Government Trades

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

AKRO

HEES

OKLO


Mid-cap stocks don’t get the same headlines as large caps but move aggressively in both directions, creating outsized opportunities for investors. Unlike their mega-cap counterparts, which tend to grind higher or

3 Mid-Caps Worth Watching Closely in March

Brinker

Equities

Mid Cap

News

Movers

Trading Ideas

Brighthouse Financial, Inc. - Common Stock

Hims & Hers Health, Inc. Class A Common Stock

HIMS

SGRY

VIAV

Check out this week&#39;s top-performing mid-cap stocks, including Akero Therapeutics&#39; remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.

Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?

Royal Caribbean Cruises

Intraday Update

Markets

AESI

BlackSky Technology Inc. Class A Common Stock

BKSY

EXOD

RADX

VSCO

Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday

McDonald's

Price Target

Pre-Market Outlook

Analyst Ratings

ADSK

CIEN

LULU

SOFI

McDonald&#39;s To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday

S&P 500

Earnings

Eurozone

Commodities

ALLK

DADA

ELAB

VERU

S&amp;P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher

Wall Street_Dow

Dow Edges Higher; AT&amp;T Posts Upbeat Earnings

Stock Movers

ETNB

EVER

HAIN

LGIH

LGTY

PTLO

TITN

TKNO

TREE

Dada Nexus, Titan Machinery, AT&amp;T And Other Big Stocks Moving Higher On Monday

Closeup,Of,Wall,St.,Street,Sign,And,Large,New,York

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

Biotech

Health Care

General

Akero&#39;s SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver fibrosis and safety.

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here&#39;s Why

movers image

BGNE

CURV

DOGZ

PSNY

VNOM

Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

Akero Therapeutics Inc

Akropolis

Press Releases

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Kuehn Law Encourages Investors of Akero Therapeutics, Inc. to Contact Law Firm

Legal

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Financing

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino's Pizza Corp. (NASDAQ: DPZ)

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Government Trades

Akero Therapeutics Inc

top performing AKRO trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga